Hims & Hers Health (NYSE:HIMS) Stock Price Down 6% Following Analyst Downgrade

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) fell 6% during mid-day trading on Tuesday after TD Cowen lowered their price target on the stock from $30.00 to $20.00. TD Cowen currently has a hold rating on the stock. Hims & Hers Health traded as low as $18.11 and last traded at $18.1760. 26,490,284 shares were traded during mid-day trading, an increase of 3% from the average session volume of 25,699,619 shares. The stock had previously closed at $19.33.

Other analysts have also recently issued reports about the company. Citigroup decreased their price objective on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a research report on Monday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. BTIG Research lowered their price objective on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, KeyCorp initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $39.32.

Insider Transactions at Hims & Hers Health

In related news, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the sale, the insider owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 9,067 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78. Following the transaction, the chief financial officer owned 91,617 shares in the company, valued at $2,779,659.78. The trade was a 9.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 129,337 shares of company stock valued at $4,651,648. 17.71% of the stock is owned by company insiders.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers pulled its compounded oral semaglutide offering and said it has held “constructive conversations” with stakeholders — a quick damage‑control move that reduces near‑term regulatory exposure. Hims & Hers is scrapping plan for knockoff Wegovy weight-loss pill. Here’s why
• Positive Sentiment: Some analysts/commentators argue the market is overreacting because GLP‑1 weight‑loss was only a portion of revenue and the company’s broader telehealth platform remains intact. That view supports longer‑term recovery potential if legal/regulatory issues are contained. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Some analysts and commentators say the company will survive but warn of a painful reset (“washout”) in the stock while management addresses regulatory/legal fallout. That implies more volatility ahead rather than binary insolvency risk. Hims & Hers Health: The Company Will Survive, But Investors Should Expect A ‘Washout’
• Negative Sentiment: Novo Nordisk filed a U.S. patent lawsuit seeking to block Hims & Hers’ compounded semaglutide products and recover damages — this escalates litigation risk and could lead to injunctions or material liability. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Negative Sentiment: Multiple major outlets report Novo Nordisk’s broader legal offensive and threats that directly target Hims’ GLP‑1 initiative — raising the probability of costly, precedent‑setting litigation. Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
• Negative Sentiment: The FDA issued a warning letter related to Hims’ activities around compounded GLP‑1 products, which increases regulatory uncertainty and could prompt additional enforcement or restrictions. Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
• Negative Sentiment: Analysts have trimmed price targets and ratings (Citigroup, TD Cowen, BofA among others) citing higher legal/regulatory risk and revenue uncertainty — a catalyst for further selling pressure. FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast
• Negative Sentiment: Shareholder litigation/fraud investigations have been announced, potentially adding legal costs and management distraction. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation
• Negative Sentiment: Market reaction: heavy volume, steep declines to multi‑month lows and elevated volatility reflect rapid de‑risking by investors; near‑term sentiment will track legal filings and any FDA follow‑ups. Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Institutional Trading of Hims & Hers Health

Several large investors have recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Hims & Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC grew its stake in Hims & Hers Health by 6.1% in the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock valued at $232,000 after acquiring an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC increased its holdings in Hims & Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock valued at $793,000 after acquiring an additional 252 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 44.7% during the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after acquiring an additional 283 shares during the last quarter. Finally, Bessemer Group Inc. raised its position in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 10.8%

The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm’s 50-day moving average price is $32.22 and its 200 day moving average price is $42.77. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of 31.93, a price-to-earnings-growth ratio of 3.21 and a beta of 2.43.

Hims & Hers Health announced that its Board of Directors has approved a share repurchase program on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.